DASATINIB INHIBITS THE GROWTH OF MOLECULARLY HETEROGENEOUS MYELOID LEUKEMIAS

PURPOSE: Dasatinib is a dual Src/Abl inhibitor, recently approved for Bcr-Abl+ leukemias with resistance or intolerance to prior therapy. Because Src kinases contribute to multiple blood cell functions by triggering a variety of signaling pathways, we hypothesized that their molecular targeting migh...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Guerrouahen, Bella S., Futami, Muneyoshi, Vaklavas, Christos, Kanerva, Jukka, Whichard, Zakary L., Nwawka, Kenechi, Blanchard, Elisabeth G., Lee, Francis Y., Robinson, Lisa J., Arceci, Robert, Kornblau, Steven M., Wieder, Eric, Cayre, Yvon E., Corey, Seth J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2988651/
https://ncbi.nlm.nih.gov/pubmed/20145167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2416
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы